Key points are not available for this paper at this time.
Introduction 0.05) and maintained at 12 months (6.9 lbs, p0.05). Reduction in ALT was also observed at 6 months (14.38 U/L, p0.05) and 12 months (20.15 U/L, p0.05). Reductions were seen in Hemoglobin A1c (0.26%, p0.05), Low-Density Lipoprotein (9.23mg/dL, p0.05), and Triglycerides (16.63mg/dL, p=0.0629) at 12 months. Conclusion: Patients referred to this novel clinical pharmacy service demonstrated significant and sustained weight and ALT reduction at 12 months, which may translate into MASLD improvement. They also experienced significant improvements in most cardiovascular clinical parameters. Disclosure S. Sallam: None. A. Ahmed: Advisory Panel; Novo Nordisk. X. Gu: None.
Sallam et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: